Do VC groups love the Web more than biotech?

CNET's Jim Kerstetter takes a look at biotech's anemic performance in the latest round of M&A deals and concludes that the investment crowd just loves the Internet more. There were 41 M&A deals in the first quarter for IT companies compared to just five in the life sciences. The reason? Kerstetter is betting that investors just feel a lot more comfortable now when they can look to an Internet play to pay off in two or three years. That kind of return is just about unheard of in the biotech space, where years of labor and high risk are a common feature of the industry. Of course, the life sciences industry as a whole attracted $9.1 billion in 862 deals last year, according to Thomson Financial and the NVCA. That's almost a third of all venture investing last year and a big increase over 2006's $7.6 billion. But that's long-term investment money, says Kerstetter. And VCs see the Web as the safer call these days.  

- check out the opinions at CNET

Related Articles:
Rocky market puts freeze on biotech deal-making. Report
Dealmaking stays big even as the markets tremble. Report
Billion-dollar baby: Biotech still on a roll with VC funds. Report
Deal-making hits a faster pace in '07. Report
Top 20 VC deals of 2007. Report

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.